275eP The clinical impact of minimal residual disease (MRD) testing on the decision-making process in non-small cell lung cancer (NSCLC)
Minimal residual disease (MRD) assessment is an emerging tool for refining risk of relapse following definitive therapy in non-small cell lung cancer (NSCLC). However, data regarding its clinical impact on decision-making process remains limited. We evaluated MRD feasibility and impact in the real-world setting.
Authors
- Noam Asna (ORCID: https://orcid.org/0009-0007-1720-069X)
- Afifi Basel
- E. Dudnik
- R. Gillis
- N. Peled
- R. Bashir
- A. Yaacov
Institutions
- Assuta Medical Center (IL)
- Shaare Zedek Medical Center (IL)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106583
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00